Syros Pharmaceuticals, Inc.(SYRS)Earnings, Financials & Key Ratios
SYRS•NASDAQ
$0.00
$10733 mkt cap·Price updated May 6, 2026
AboutSyros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$10M-33.2%
- EBITDA-$127M+4.6%
- Net Income-$165M-73.9%
- EPS (Diluted)-5.81+22.4%
- Gross Margin77.33%-3.4%
- EBITDA Margin-1275.52%-42.8%
- Operating Margin-1298.19%-42.2%
- Net Margin-1656.34%-160.4%
- ROE-227.95%-156.4%
- Debt/Equity3.73+648.6%
- Interest Coverage-25.16+23.5%
SYRS Key Insights
Syros Pharmaceuticals, Inc. (SYRS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 37.1%
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗High debt to equity ratio of 3.7x
- ✗Weak Piotroski F-Score: 1/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
SYRS Price & Volume
Syros Pharmaceuticals, Inc. (SYRS) stock price & volume — 10-year historical chart
Loading chart...
SYRS Growth Metrics
Syros Pharmaceuticals, Inc. (SYRS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years37.12%
3 Years-13.01%
TTM-90.54%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-53.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-32.68%
Return on Capital
10 Years-67.75%
5 Years-66.8%
3 Years-69.44%
Last Year-74.73%
SYRS Peer Comparison
Syros Pharmaceuticals, Inc. (SYRS) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 TNGX | 3.21B | 23.62 | -27.15 | 48.29% | -162.85% | -50.3% | 0.10 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 |
Compare SYRS vs Peers
Syros Pharmaceuticals, Inc. (SYRS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SYRS Income Statement
Syros Pharmaceuticals, Inc. (SYRS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 317K | 317K | 1.1M | 2.05M | 1.98M | 15.09M | 23.49M | 14.88M | 9.94M | 386K |
| Revenue Growth % | - | 0% | 247.32% | 86.19% | -3.32% | 661.5% | 55.62% | -36.65% | -33.23% | -90.54% |
| Cost of Goods Sold | 602K | 0 | 1.53M | 0 | 0 | 0 | 0 | 2.97M | 2.25M | 1.27M |
| COGS % of Revenue | 189.91% | - | 138.69% | - | - | - | - | 19.94% | 22.67% | - |
| Gross Profit | -285K▲ 0% | 317K▲ 211.2% | -426K▼ 234.4% | 2.05M▲ 581.2% | 1.98M▼ 3.3% | 15.09M▲ 661.5% | 23.49M▲ 55.6% | 11.91M▼ 49.3% | 7.68M▼ 35.5% | -883K▲ 0% |
| Gross Margin % | -89.91% | 100% | -38.69% | 100% | 100% | 100% | 100% | 80.06% | 77.33% | -228.76% |
| Gross Profit Growth % | - | 211.23% | -234.38% | 581.22% | -3.32% | 661.5% | 55.62% | -49.28% | -35.5% | - |
| Operating Expenses | 30.14M | 48.28M | 55.79M | 66.35M | 79.72M | 97.39M | 122.91M | 38.81M | 30.77M | 111.3M |
| OpEx % of Revenue | 9506.94% | 15230.28% | 5066.94% | 3236.39% | 4022.35% | 645.27% | 523.28% | 260.81% | 309.69% | - |
| Selling, General & Admin | 5.73M | 10.46M | 13.89M | 16.16M | 21.48M | 21.32M | 23.04M | 29.3M | 28.28M | 23.27M |
| SG&A % of Revenue | 1807.26% | 3300.63% | 1261.67% | 788.49% | 1083.65% | 141.29% | 98.08% | 196.9% | 284.64% | - |
| Research & Development | 24.41M | 37.82M | 41.9M | 50.18M | 58.24M | 76.06M | 99.87M | 111.94M | 108.15M | 88.03M |
| R&D % of Revenue | 7699.68% | 11929.65% | 3805.27% | 2447.9% | 2938.7% | 503.98% | 425.2% | 752.31% | 1088.5% | - |
| Other Operating Expenses | 2K | 220K | 676K | 0 | 0 | 0 | 0 | -102.43M | -105.66M | 0 |
| Operating Income | -29.82M▲ 0% | -47.96M▼ 60.8% | -54.69M▼ 14.0% | -64.3M▼ 17.6% | -77.74M▼ 20.9% | -82.3M▼ 5.9% | -99.42M▼ 20.8% | -135.87M▼ 36.7% | -128.99M▲ 5.1% | -111.52M▲ 0% |
| Operating Margin % | -9406.94% | -15130.28% | -4966.94% | -3136.39% | -3922.35% | -545.27% | -423.28% | -913.13% | -1298.19% | -28892.23% |
| Operating Income Growth % | -121.96% | -60.84% | -14.02% | -17.57% | -20.91% | -5.86% | -20.81% | -36.67% | 5.07% | - |
| EBITDA | -29.22M | -46.69M | -53.16M | -62.69M | -75.02M | -79.26M | -96.4M | -132.91M | -126.74M | -110.25M |
| EBITDA Margin % | -9217.03% | -14728.71% | -4828.25% | -3058.15% | -3785.02% | -525.16% | -410.43% | -893.19% | -1275.52% | -28563.47% |
| EBITDA Growth % | -121.73% | -59.8% | -13.86% | -17.93% | -19.66% | -5.66% | -21.62% | -37.87% | 4.64% | 18.39% |
| D&A (Non-Cash Add-back) | 602K | 1.27M | 1.53M | 1.6M | 2.72M | 3.04M | 3.02M | 2.97M | 2.25M | 1.27M |
| EBIT | -29.82M | -47.96M | -54.69M | -62.28M | -75.44M | -82.25M | -82.65M | -90.52M | -159.45M | -92.48M |
| Net Interest Income | 0 | 0 | 0 | 2.02M | 2.3M | -1.37M | -3.82M | -2M | 1.69M | -623K |
| Interest Income | 0 | 0 | 0 | 2.02M | 2.3M | 426K | 87K | 2.13M | 6.82M | 4.71M |
| Interest Expense | 0 | 0 | 0 | 1K | 0 | 1.79M | 3.91M | 4.13M | 5.13M | 5.33M |
| Other Income/Expense | 2K | 220K | 676K | 2.02M | 2.3M | -1.74M | 12.86M | 41.22M | -35.59M | 13.84M |
| Pretax Income | -29.82M▲ 0% | -47.74M▼ 60.1% | -54.01M▼ 13.1% | -62.28M▼ 15.3% | -75.44M▼ 21.1% | -84.04M▼ 11.4% | -86.56M▼ 3.0% | -94.65M▼ 9.4% | -164.57M▼ 73.9% | -97.81M▲ 0% |
| Pretax Margin % | -9406.31% | -15060.88% | -4905.54% | -3038% | -3806.16% | -556.8% | -368.52% | -636.12% | -1656.34% | -25340.67% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -29.82M▲ 0% | -47.74M▼ 60.1% | -54.01M▼ 13.1% | -62.28M▼ 15.3% | -75.44M▼ 21.1% | -84.04M▼ 11.4% | -86.56M▼ 3.0% | -94.65M▼ 9.4% | -164.57M▼ 73.9% | -97.81M▲ 0% |
| Net Margin % | -9406.31% | -15060.88% | -4905.54% | -3038% | -3806.16% | -556.8% | -368.52% | -636.12% | -1656.34% | -25340.67% |
| Net Income Growth % | -122.01% | -60.11% | -13.13% | -15.31% | -21.13% | -11.4% | -3% | -9.35% | -73.87% | -53.44% |
| Net Income (Continuing) | -29.82M | -47.74M | -54.01M | -62.28M | -75.44M | -84.04M | -86.56M | -94.65M | -164.57M | -97.81M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -120.45▲ 0% | -37.60▲ 68.8% | -21.26▲ 43.5% | -19.07▲ 10.3% | -18.76▲ 1.6% | -18.25▲ 2.7% | -13.84▲ 24.2% | -7.49▲ 45.9% | -5.81▲ 22.4% | -2.49▲ 0% |
| EPS Growth % | -122.03% | 68.78% | 43.46% | 10.3% | 1.63% | 2.72% | 24.16% | 45.88% | 22.43% | -32.68% |
| EPS (Basic) | -120.45 | -37.60 | -21.26 | -19.07 | -18.76 | -18.25 | -13.84 | -7.49 | -5.81 | - |
| Diluted Shares Outstanding | 247.56K | 1.27M | 2.54M | 3.27M | 4.02M | 4.61M | 6.25M | 12.63M | 28.33M | 39.34M |
| Basic Shares Outstanding | 247.56K | 1.27M | 2.54M | 3.27M | 4.02M | 4.61M | 6.25M | 12.63M | 28.33M | 39.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SYRS Balance Sheet
Syros Pharmaceuticals, Inc. (SYRS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 36.45M | 85.51M | 73.16M | 101.73M | 114.51M | 178.56M | 136.59M | 211.39M | 144.98M | 63.93M |
| Cash & Short-Term Investments | 35.91M | 83.59M | 72.05M | 99.68M | 91.42M | 173.98M | 130.37M | 202.3M | 139.53M | 58.27M |
| Cash Only | 35.91M | 58.59M | 32.2M | 49.89M | 41.44M | 173.98M | 92.3M | 167.47M | 139.53M | 58.27M |
| Short-Term Investments | 0 | 25M | 39.84M | 49.79M | 49.98M | 0 | 38.07M | 34.84M | 0 | 0 |
| Accounts Receivable | 0 | 867K | 0 | 0 | 20.16M | 2.33M | 2.98M | 1.69M | 0 | 0 |
| Days Sales Outstanding | - | 998.28 | - | - | 3.71K | 56.37 | 46.29 | 41.55 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 290K | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 1.05M | 193K | 638K | 0 | 0 | 0 | 7.39M | 5.45M | 5.66M |
| Total Non-Current Assets | 7.18M | 5.82M | 5.33M | 5.03M | 35.47M | 34.69M | 46.35M | 33.09M | 23.19M | 21.06M |
| Property, Plant & Equipment | 4.8M | 4.85M | 3.94M | 3.86M | 31.89M | 29.64M | 27.29M | 24.66M | 19.48M | 17.58M |
| Fixed Asset Turnover | 0.07x | 0.07x | 0.28x | 0.53x | 0.06x | 0.51x | 0.86x | 0.60x | 0.51x | 0.02x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 483K | 483K | 290K | 290K | 3.09M | 3.09M | 13.04M | 3.09M | 2.12M | 8.48M |
| Other Non-Current Assets | 1.9M | 482K | 1.1M | 881K | 490K | 1.97M | 6.03M | 5.35M | 1.59M | 5.97M |
| Total Assets | 43.63M▲ 0% | 91.32M▲ 109.3% | 78.49M▼ 14.1% | 106.77M▲ 36.0% | 149.98M▲ 40.5% | 213.25M▲ 42.2% | 182.94M▼ 14.2% | 244.49M▲ 33.6% | 168.17M▼ 31.2% | 85M▲ 0% |
| Asset Turnover | 0.01x | 0.00x | 0.01x | 0.02x | 0.01x | 0.07x | 0.13x | 0.06x | 0.06x | 0.00x |
| Asset Growth % | -29.05% | 109.31% | -14.05% | 36.03% | 40.47% | 42.19% | -14.22% | 33.65% | -31.21% | -149.12% |
| Total Current Liabilities | 7.96M | 9.57M | 12.41M | 19.53M | 23.52M | 28.62M | 31.51M | 30.78M | 36.68M | 28.39M |
| Accounts Payable | 5.04M | 2.42M | 2.28M | 3.31M | 5.85M | 3.6M | 3.69M | 6.41M | 11.54M | 9.65M |
| Days Payables Outstanding | 3.05K | - | 545.71 | - | - | - | - | 788.68 | 1.87K | 2.88K |
| Short-Term Debt | 0 | 168K | 47K | 9K | 1.28M | 1.73M | 0 | 0 | 6.67M | 0 |
| Deferred Revenue (Current) | 0 | 550K | 355K | 1.93M | 5.74M | 12.21M | 10.18M | 4.33M | 0 | 0 |
| Other Current Liabilities | 284K | 4.36M | 7.54M | 11.29M | 5.19M | 3.99M | 9.28M | 9.44M | 6.99M | 0 |
| Current Ratio | 4.58x | 8.94x | 5.89x | 5.21x | 4.87x | 6.24x | 4.33x | 6.87x | 3.95x | 3.95x |
| Quick Ratio | 4.58x | 8.94x | 5.89x | 5.21x | 4.86x | 6.24x | 4.33x | 6.87x | 3.95x | 3.95x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1.63M | 1.15M | 751K | 8.65M | 47.28M | 94.07M | 66.21M | 85.97M | 114.83M | 67.73M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 39.55M | 40.26M | 40.65M | 34.56M | 41.08M |
| Capital Lease Obligations | 206K | 53K | 6K | 22K | 24.64M | 24.93M | 22.92M | 20.85M | 18.53M | 70.21M |
| Deferred Tax Liabilities | 0 | 0 | 0 | -22K | -22.64M | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.42M | 1.1M | 745K | 353K | 0 | 19.71M | 3.03M | 24.47M | 61.75M | 136.99M |
| Total Liabilities | 9.58M | 10.72M | 13.16M | 28.18M | 70.79M | 122.7M | 97.72M | 116.75M | 151.51M | 96.12M |
| Total Debt | 339K | 221K | 53K | 31K | 25.92M | 66.21M | 65.19M | 63.57M | 62.08M | 60.23M |
| Net Debt | -35.57M | -58.37M | -32.15M | -49.85M | -15.52M | -107.77M | -27.11M | -103.9M | -77.45M | 1.95M |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.00x | 0.33x | 0.73x | 0.76x | 0.50x | 3.73x | 3.73x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.55x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.02x |
| Interest Coverage | - | - | - | -64296.00x | - | -45.92x | -25.45x | -32.87x | -25.16x | -17.35x |
| Total Equity | 34.05M▲ 0% | 80.6M▲ 136.7% | 65.32M▼ 19.0% | 78.59M▲ 20.3% | 79.18M▲ 0.8% | 90.55M▲ 14.4% | 85.22M▼ 5.9% | 127.74M▲ 49.9% | 16.66M▼ 87.0% | -11.12M▲ 0% |
| Equity Growth % | -43.48% | 136.72% | -18.95% | 20.3% | 0.76% | 14.36% | -5.89% | 49.89% | -86.96% | -412.16% |
| Book Value per Share | 137.54 | 63.48 | 25.71 | 24.06 | 19.69 | 19.66 | 13.63 | 10.11 | 0.59 | -0.28 |
| Total Shareholders' Equity | 34.05M | 80.6M | 65.32M | 78.59M | 79.18M | 90.55M | 85.22M | 127.74M | 16.66M | -11.12M |
| Common Stock | 2K | 23K | 26K | 34K | 43K | 56K | 61K | 20K | 26K | 27K |
| Retained Earnings | -53.51M | -101.26M | -155.27M | -217.54M | -292.98M | -377.02M | -463.58M | -558.23M | -722.81M | -756.24M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -931K | -9K | -42K | -3K | 24K | 0 | -79K | 102K | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SYRS Cash Flow Statement
Syros Pharmaceuticals, Inc. (SYRS) cash flow — operating, investing & free cash flow history
| Line item | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -23.03M | -40.54M | -44.73M | -40.31M | -60.25M | -57.36M | -99.54M | -123.06M | -109.71M | -109.71M |
| Operating CF Margin % | -7264.98% | -12787.38% | -4062.58% | -1966.59% | -3040.01% | -380.07% | -423.79% | -827.05% | -1104.14% | - |
| Operating CF Growth % | -92.41% | -76.01% | -10.34% | 9.87% | -49.46% | 4.79% | -73.52% | -23.63% | 10.85% | 58.53% |
| Net Income | -29.82M | -47.74M | -54.01M | -62.28M | -75.44M | -84.04M | -86.56M | -94.65M | -164.57M | -97.81M |
| Depreciation & Amortization | 602K | 1.27M | 1.53M | 1.6M | 2.72M | 3.04M | 3.02M | 2.97M | 2.25M | 1.27M |
| Stock-Based Compensation | 3.23M | 4.23M | 4.42M | 6.61M | 9.84M | 10.94M | 10.35M | 11.41M | 10.43M | 7.25M |
| Deferred Taxes | 0 | 0 | 0 | 0 | -1.13M | 326K | -16.46M | 0 | 0 | 8.08M |
| Other Non-Cash Items | 17K | 10K | -102K | -642K | 7.24M | 2.32M | 706K | -37.27M | 37.13M | -22.18M |
| Working Capital Changes | 2.94M | 1.69M | 3.44M | 14.39M | -3.48M | 10.05M | -10.6M | -5.52M | 5.05M | 3.38M |
| Change in Receivables | 0 | -317K | 867K | 0 | -20.16M | 19.99M | 7K | 1.28M | 1.69M | 1.67M |
| Change in Inventory | 0 | 2.69M | 3.3M | 0 | -4.36M | -2.53M | 1.98M | -1.28M | 0 | 29K |
| Change in Payables | 2.02M | -404K | 141K | 888K | 1.49M | -1.06M | 48K | 2.77M | 5.13M | 6.79M |
| Cash from Investing | -1.18M | -27.34M | -15.59M | -10.64M | -11.73M | 46.66M | -52.65M | 67.19M | 37.34M | 1.95M |
| Capital Expenditures | -1.18M | -2.32M | -821K | -1.38M | -12.64M | -3.34M | -1.25M | -1.24M | -272K | -67K |
| CapEx % of Revenue | 370.98% | 732.49% | 74.57% | 67.51% | 637.64% | 22.1% | 5.3% | 8.34% | 2.74% | - |
| Acquisitions | 0 | 0 | 0 | 9K | 110K | 0 | 0 | 0 | 0 | 1.46M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -25.02M | -14.77M | 9K | 0 | 0 | 0 | 0 | 1.56M | 25.22M |
| Cash from Financing | -278K | 90.56M | 33.94M | 69.08M | 65.99M | 142.95M | 70.51M | 131.04M | 43.46M | 43.16M |
| Debt Issued (Net) | -50K | -135K | -168K | -50K | -205K | 39.38M | -265K | -291K | -65K | -3K |
| Equity Issued (Net) | -228K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -620K | 0 | 0 | 0 | 0 | 0 | 0 | -81K | 0 | 115K |
| Other Financing | 0 | 395K | 1.8M | 626K | 374K | 1.3M | 439K | 11.66M | 257K | -111K |
| Net Change in Cash | -24.48M▲ 0% | 22.68M▲ 192.6% | -26.38M▼ 216.3% | 18.13M▲ 168.7% | -6M▼ 133.1% | 132.25M▲ 2305.3% | -81.68M▼ 161.8% | 75.17M▲ 192.0% | -28.91M▼ 138.5% | -53.94M▲ 0% |
| Free Cash Flow | -24.21M▲ 0% | -42.86M▼ 77.1% | -45.55M▼ 6.3% | -41.7M▲ 8.5% | -72.89M▼ 74.8% | -60.7M▲ 16.7% | -100.78M▼ 66.0% | -124.31M▼ 23.3% | -109.98M▲ 11.5% | -100.06M▲ 0% |
| FCF Margin % | -7635.96% | -13519.87% | -4137.15% | -2034.1% | -3677.65% | -402.17% | -429.09% | -835.39% | -1106.87% | -25921.5% |
| FCF Growth % | -98.9% | -77.06% | -6.28% | 8.45% | -74.8% | 16.73% | -66.04% | -23.34% | 11.53% | 18.74% |
| FCF per Share | -97.78 | -33.76 | -17.93 | -12.77 | -18.12 | -13.18 | -16.12 | -9.84 | -3.88 | -3.88 |
| FCF Conversion (FCF/Net Income) | 0.77x | 0.85x | 0.83x | 0.65x | 0.80x | 0.68x | 1.15x | 1.30x | 0.67x | 1.02x |
| Interest Paid | 0 | 0 | 0 | 2K | 72K | 1.5M | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 7K | 29K | 7K | 0 | 0 | 0 | 0 |
SYRS Key Ratios
Syros Pharmaceuticals, Inc. (SYRS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -63.25% | -83.28% | -74.02% | -86.55% | -95.63% | -99.02% | -98.49% | -88.9% | -227.95% | -2746.84% |
| Return on Invested Capital (ROIC) | - | -347.32% | -148.05% | -155.8% | -126.22% | -265.81% | -364.72% | -248.71% | - | 329.92% |
| Gross Margin | -89.91% | 100% | -38.69% | 100% | 100% | 100% | 100% | 80.06% | 77.33% | -228.76% |
| Net Margin | -9406.31% | -15060.88% | -4905.54% | -3038% | -3806.16% | -556.8% | -368.52% | -636.12% | -1656.34% | -25340.67% |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.00x | 0.33x | 0.73x | 0.76x | 0.50x | 3.73x | 3.73x |
| Interest Coverage | - | - | - | -64296.00x | - | -45.92x | -25.45x | -32.87x | -25.16x | -17.35x |
| FCF Conversion | 0.77x | 0.85x | 0.83x | 0.65x | 0.80x | 0.68x | 1.15x | 1.30x | 0.67x | 1.02x |
| Revenue Growth | - | 0% | 247.32% | 86.19% | -3.32% | 661.5% | 55.62% | -36.65% | -33.23% | -90.54% |
SYRS Frequently Asked Questions
Syros Pharmaceuticals, Inc. (SYRS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Syros Pharmaceuticals, Inc. (SYRS) reported $0.4M in revenue for fiscal year 2023.
Syros Pharmaceuticals, Inc. (SYRS) saw revenue decline by 33.2% over the past year.
Syros Pharmaceuticals, Inc. (SYRS) reported a net loss of $97.8M for fiscal year 2023.
Dividend & Returns
Syros Pharmaceuticals, Inc. (SYRS) has a return on equity (ROE) of -227.9%. Negative ROE indicates the company is unprofitable.
Syros Pharmaceuticals, Inc. (SYRS) had negative free cash flow of $100.1M in fiscal year 2023, likely due to heavy capital investments.
Explore More SYRS
Syros Pharmaceuticals, Inc. (SYRS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates